High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Najat Khan: Good morning, everyone, and thank you for joining us. First, we're focusing on signal over noise, generating proof and proof points across our both wholly owned programs and our partner programs with the goal to showcase where AI can truly make a difference in creating value.
Recursion Pharmaceuticals (NASDAQ:RXRX) leadership used its latest earnings call to emphasize a sharper focus on translating artificial intelligence-enabled discovery into clinical and partnership “proof points,” while maintaining what it described as tighter financial discipline. CEO and President
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.